Loading...
•
Dec 31, 2020
Viridian Therapeutics Q4 2020 Earnings Report
Reported financial results for the fourth quarter and year ended December 31, 2020 and provided corporate updates.
Key Takeaways
Viridian Therapeutics reported a net loss of $90.7 million for the fourth quarter of 2020. The company's cash, cash equivalents, and short-term investments totaled $127.6 million as of December 31, 2020, providing runway into the second half of 2023.
Progressed lead programs VRDN-001 and VRDN-002 towards clinical trials in Thyroid Eye Disease (TED) with IND filings expected by the end of 2021.
Completed integration and name change to Viridian Therapeutics following October 2020 merger and concurrent financing.
Ended 2020 with a strong cash position of $127.6 million, providing runway into the second half of 2023.
Strengthened leadership team with the appointment of Dr. Jonathan Violin as CEO and additions of Dr. Barrett Katz as CMO and Dr. Vahe Bedian as Chief Scientist
Revenue by Segment
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...